接种疫苗
医学
随机对照试验
家庭医学
社会经济地位
人口学
干预(咨询)
儿科
人口
环境卫生
免疫学
内科学
护理部
社会学
作者
Zhiyuan Hou,Zhendong Wu,Zhiqiang Qu,Liubing Gong,Hui Peng,Mark Jit,Heidi J. Larson,Joseph T. Wu,Leesa Lin
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2025-04-07
卷期号:31 (6): 1855-1862
被引量:9
标识
DOI:10.1038/s41591-025-03618-6
摘要
Abstract Conversational artificial intelligence, in the form of chatbots powered by large language models, offers a new approach to facilitating human-like interactions, yet its efficacy in enhancing vaccination uptake remains under-investigated. This study assesses the effectiveness of a vaccine chatbot in improving human papillomavirus (HPV) vaccination among female middle school students aged 12–15 years across diverse socioeconomic settings in China, where HPV vaccination is primarily paid out-of-pocket. A school-based cluster randomized trial was conducted from 18 January to 31 May 2024. The study included 2,671 parents from 180 middle school classes stratified by socioeconomic setting, school and grade level in Shanghai megacity, and urban and rural regions of Anhui Province. Participants were randomly assigned to either the intervention group (90 classes, 1,294 parents), which engaged with the chatbot for two weeks, or the control group (90 classes, 1,377 parents), which received usual care. The primary outcome was the receipt or scheduled appointment of the HPV vaccine for participants’ daughters. In intention-to-treat analyses, 7.1% of the intervention group met this outcome versus 1.8% of the control group ( P < 0.001) over a two-week intervention period. In addition, there was a statistically significant increase in HPV vaccination-specific consultations with health professionals (49.1% versus 17.6%, P < 0.001), along with enhanced vaccine literacy ( P < 0.001) and rumor discernment ( P < 0.001) among participants using the chatbot. These findings indicate that the chatbot effectively increased vaccination and improved parental vaccine literacy, although further research is necessary to scale and sustain these gains. Clinical trial registration: NCT06227689 .
科研通智能强力驱动
Strongly Powered by AbleSci AI